Clinical Trials Directory

Trials / Terminated

TerminatedNCT04060342

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination With an Anti-PD-1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 With Standard of Care or in Combination With an Anti-PD-1 Antibody in Patients With Specified Metastatic Solid Tumors

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
61 (actual)
Sponsor
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma followed by a Phase 2 Basket Expansion phase in Patients with Specified Metastatic Solid Tumors

Detailed description

Note: The Phase 2 portion of the study was not initiated.

Conditions

Interventions

TypeNameDescription
DRUGGB1275Oral
DRUGnab-paclitaxel and gemcitabineIV infusion
DRUGpembrolizumabIV infusion

Timeline

Start date
2019-08-13
Primary completion
2022-04-11
Completion
2022-04-11
First posted
2019-08-19
Last updated
2022-08-18

Locations

8 sites across 2 countries: United States, United Kingdom

Regulatory

Source: ClinicalTrials.gov record NCT04060342. Inclusion in this directory is not an endorsement.